Novel T-cell receptor program expands Cellantra’s precision oncology pipeline and is designed to recognize a cancer-associated MAGE-C2 antigen presented by HLA-A*02:01
Cellantra, an in vivo gene therapy and next-generation immuno-oncology biotechnology company, today announced the discovery and development of a potent novel T-cell receptor (TCR) candidate directed against MAGE-C2, also known as CT10, a cancer-testis antigen associated with multiple malignancies.
The lead discovery candidate is designed to recognize a MAGE-C2-derived peptide presented by HLA-A*02:01, enabling antigen-specific recognition of tumor cells displaying the intended peptide-HLA complex. Published studies have identified HLA-A2-restricted MAGE-C2 epitopes and shown that MAGE-C2/HLA-A2-specific TCRs can redirect human T cells toward antigen-positive tumor targets, providing a strong biological foundation for MAGE-C2-directed T-cell therapies.
A Potent TCR Candidate Engineered for Precision Cancer Recognition
Cellantra developed the MAGE-C2 TCR program using its integrated computational immunology, TCR-discovery and protein-engineering platform to identify and optimize receptor architectures capable of selectively engaging the intended peptide-HLA complex.
The lead candidate emerged from the company’s discovery-stage screening as a high-priority, potency-focused TCR with a predicted interaction and selectivity profile consistent with strong target engagement. Cellantra is now advancing the program through experimental functional testing, specificity assessment, cross-reactivity analysis and safety-focused validation before determining the appropriate path toward formal preclinical development.
The program is being developed around several core objectives:
• potent, antigen-dependent T-cell activation against cells presenting the intended MAGE-C2 peptide-HLA complex;
• highly selective recognition of the intended MAGE-C2/HLA-A*02:01 target;
• discrimination against unrelated peptide-HLA complexes and antigen-negative control cells;
• systematic evaluation of peptide cross-reactivity, potential off-target recognition and normal-tissue risk; and
• compatibility with future engineered T-cell and in vivo immune-cell programming strategies.
MAGE-C2 is a member of the cancer-testis antigen family, a class of tumor-associated antigens characterized by limited expression in most normal adult tissues and re-expression in multiple cancers. MAGE-C2 has been investigated as an immune target in melanoma, multiple myeloma and other MAGE-C2-positive malignancies, and published work has established that MAGE-C2-derived peptides can be naturally processed and presented to cytotoxic T cells.
Expanding the Cellantra Precision Immuno-Oncology Pipeline
The MAGE-C2 program represents an expansion of Cellantra’s broader effort to build programmable, antigen-directed cancer therapies capable of accessing targets beyond the conventional cell-surface antigen space.
TCR-based approaches can recognize peptide fragments derived from intracellular proteins after those proteins are processed and displayed by HLA molecules on the cell surface. This mechanism potentially opens a much larger universe of cancer-associated proteins to immune-based therapeutics than approaches limited to extracellular targets.
Cellantra believes that combining precision TCR discovery with advanced gene-delivery and immune-cell engineering technologies could provide a flexible framework for addressing tumors that remain difficult to treat with conventional surface-antigen strategies.
“The discovery of a potent MAGE-C2-directed TCR candidate is an important addition to our precision immuno-oncology pipeline. Our strategy is to identify biologically compelling intracellular cancer targets, engineer highly selective recognition systems, and ultimately connect those systems with technologies capable of programming therapeutic activity in vivo,” the company said. “MAGE-C2 is especially attractive because of its cancer-associated expression profile and the existing biological evidence for HLA-restricted T-cell recognition. Our next priority is to demonstrate that potency is accompanied by the specificity and safety profile required for further development.”
Building Toward Experimental and Preclinical Validation
Cellantra will next focus on experimental confirmation of target binding, TCR expression, antigen-dependent T-cell activation, tumor-cell recognition, selectivity and comprehensive off-target assessment. The company also intends to evaluate the candidate across relevant antigen-density conditions and matched negative-control systems to better define its functional window.
These studies are intended to determine whether the candidate satisfies the company’s internal criteria for advancement into broader preclinical development and whether additional receptor optimization is warranted before selecting a development configuration.
The MAGE-C2 TCR candidate is investigational and has not been approved for therapeutic use. Clinical safety or efficacy has not been established. The description of the candidate as “potent” reflects a discovery-stage program characterization and does not constitute evidence of clinical benefit.
About Cellantra
Cellantra is a biotechnology company developing next-generation in vivo gene therapy and precision immuno-oncology technologies. The company is building a pipeline spanning engineered T-cell receptor programs, intracellular cancer-targeting therapeutics, in vivo immune-cell programming and advanced nucleic-acid delivery technologies.
Cellantra’s research strategy combines computational molecular design, targeted delivery and experimental validation with the long-term objective of transforming complex biological discoveries into new therapeutic modalities.
Cellantra – Make the World a Better Place.
Forward-Looking Statements
This press release contains forward-looking statements regarding Cellantra’s research programs, technology platforms, development plans and potential therapeutic applications. These statements involve scientific, technical, regulatory and development uncertainties. Computational results, discovery-stage candidate assessments and early experimental findings may not predict subsequent preclinical or clinical outcomes. Cellantra’s investigational programs have not been demonstrated to be safe or effective in humans, and no assurance can be given that any program will successfully advance into or through clinical development.
